Johnson & Johnson (JNJ) earnings Q1 2023

Arthur Widak | OnlyPhoto | Getty Images

Johnson&Johnson reported adjusted earnings and revenue that topped Wall Street’s expectations on Tuesday, and lifted its full-year forecast as it cited strong growth across all business units led by its pharmaceutical arm.

J&J, whose financial results are considered a bellwether for many health companies, said its first-quarter sales grew 5.6% over the same quarter last year.

The consumer staples giant reported a net loss of $68 million, or 3 cents per share, related to its talc baby powder liabilities and costs tied to the upcoming spin-off of its consumer health business. That compares to a net income of $5.2 billion, or $1.93 per share, for the same period a year ago. Excluding certain items, adjusted earnings per share were $2.68 for the period.

Here’s how J&J results compared with Wall Street expectations based on a survey of analysts by Refinitiv:

  • Earnings per share: $2.68 adjusted vs $2.50 expected
  • Revenue: $24.75 billion, vs. $23.67 billion expected

J&J is now forecasting 2023 sales of $97.9 billion to $98.9 billion, about $1 billion higher than the guidance provided in January. The company raised its full-year adjusted earnings outlook to $10.60 to $10.70 per share, from a previous forecast of $10.45 to $10.65.

The company’s shares were roughly flat in premarket trading. The stock is down more than 6% for the year through Monday’s close, putting the company’s market value at roughly $430 billion.

CFO Joseph Wolk told CNBC on Tuesday that J&J raised its guidance due to strong growth across all three business sectors — consumer health, pharmaceuticals and medical devices.

“If you think about how we started the year and guidance in January, we were responsibly cautious,” he said on “Squawk Box.” “First-quarter growth was much stronger than even fourth-quarter growth for all three business units, and our positions kind of change to responsibly optimistic at this point. We feel very good about 2023.”

He added that data being produced on J&J’s drug for the cancer multiple myeloma and procedural data in its medical devices unit make the company “feel very, very good about what lies beyond 2023.”

J&J reported $13.4 billion in pharmaceutical sales, which grew more than 4% over the same quarter last year. The company said that increase was driven by sales of Darzalex, a biologic for the treatment of multiple myeloma, and the blockbuster drug Stelara, which is used to treat a number of immune-mediated inflammatory diseases.

J&J will lose patent protection on Stelara later this year. During a conference call, Wolk said the company is “committed to growing through the loss.”

Sales for the company’s medical devices business rose to nearly $7.5 billion, up 7.3% from the first quarter of 2022. J&J said its acquisition of Abiomed, a cardiovascular medical technology company, in December last year fueled that rise.

J&J’s consumer health business, which it is spinning off into a separate publicly traded company this year, reported about $3.8 billion in sales. That unit grew 7.4% over the same period last year, primarily driven by over-the-counter products like Tylenol and skin health products under brands like Neutrogena and Aveeno.

Wolk told CNBC the company is making “great progress” on the separation of its consumer health business. But J&J hasn’t been clear about when exactly the split will happen.

J&J also announced its board has approved a 5.3% quarterly dividend increase, to $1.19 per share, due to the company’s strong 2022 performance.

The New Brunswick, New Jersey-based company entered this earnings season with its shares on the rise after it offered more clarity on the long-running legal fight over its talc-based baby powder products. Earlier this month, J&J proposed to pay nearly $9 billion over the next 25 years to settle thousands of allegations that its baby powder and other talc products caused cancer.

Read the full J&J earnings report.

Comments are closed.